ArticleNeuropsychology2023
The "when" matters: Evidence from memory markers in the clinical continuum of Alzheimer's disease.
Article in Neuropsychology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Commonalities and Divergences in the Cognitive Profiles of Autism and Dementia: Protocol for a Narrative Literature Review.JMIR research protocols · 2026Article
- Activities of daily living and their neural correlates across the Alzheimer's disease continuum: Evidence from a Latin American cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Short-term memory conjunctive binding in subjective cognitive decline: A PET biomarker-based study.Journal of neurology · 2026Article
- Examining the Cognitive Underpinnings of Functional Decline in Prodromal Alzheimer's Disease: Insights From the Details of Functions of Everyday Life (DoFEL) Scale.Journal of aging research · 2025Article
- Eye movements powered by artificial intelligence identify asymptomatic carriers of familial Alzheimer's disease.Brain communications · 2025Article
- The memory binding test in a longitudinal study of cognitive aging and preclinical disease.Neuropsychology · 2024Article
- Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults.The journal of prevention of Alzheimer's disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
objectiveCognitive assessment able to detect impairments in the early neuropathological stages of Alzheimer's disease (AD) is urgently needed. The visual short-term memory binding task (VSTMBT) and the Free and Cued Selective Reminding Test (FCSRT) have been recommended by the neurodegenerative disease working group as promising tests to aid in the early detection of AD. In this study, we investigated their complementary value across the clinical stages of the AD continuum.
methodOne hundred and seventeen older adults with subjective cognitive complaint (SCC), 79 with mild cognitive impairment (MCI), 31 patients with AD dementia (ADD), and 37 cognitively unimpaired (CU) subjects, underwent assessment with the VSTMBT and the picture version of the Spanish FCSRT.
resultsAfter controlling for multiple comparisons, significant differences were found across groups. The VSTMBT was the only test that "marginally" differentiated between CU and SCC (
conclusionsOur results suggest that the VSTMBT and the FCSRT are sensitive to the clinical continuum of AD. Whereas the former detects changes in the early prodromal stages, the latter is more sensitive to the advanced prodromal stages of AD. These novel tests can aid in the early detection, monitor disease progression and response to treatment, and thus support drug development programs. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.